- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
10 Drugs Approved for Primary Care: Q1 2025
Review 10 new FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for UTIs, acute pain, and more.
The first quarter of 2025 brought a wave of new FDA drug approvals, several of which have direct relevance for primary care. In this slideshow, we highlight 10 new therapies that may soon find a place in your prescribing routine. Click through the slides above for details on the first new oral antibiotic for uncomplicated urinary tract infections in 30 years, a first-in-class nonopioid analgesic indicated for moderate-to-severe acute pain, a vaccine that provides coverage against 5 major serogroups of Neisseria meningitidis that affect young people, and 7 more.
FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment
October 14th 2025FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.
